Table 45Characteristics of metformin/sitagliptin dual therapy active-control trials in adults with type 2 diabetes

Author, year Country
Quality
Sample size (N)
Follow-up (weeks)
Age (years) (SD)
% Femalea
% Whitea
% Hispanica
Other population characteristics
InterventionControl(s)
Goldstein 200731
Multinational
Fair
1,091
24
53.2–54.1 (9.6–10.2)
44.7–57.7
46.0–58.2
21.4–30.2
Dual therapy (sitagliptin + metformin): 100 mg/1,000 mg daily 100 mg/2,000 mg dailySitagliptin: 100 mg daily

Metformin:
1,000 mg daily
2,000 mg daily
Williams- Herman 58432
Multinational
Fair
670 (748)
54
53.5–54.2 (9.1–10.0)
47–59
NR
NR
Dual therapy (sitagliptin + metformin): 100 mg/1,000 mg daily 100 mg/2,000 mg dailySitagliptin: 100 mg daily

Metformin:
1,000 mg daily
2,000 mg daily
Williams- Herman, 201033c
Multinational
Fair
517
104
53.9–55.9(8.6–11.0)
42–63
NR
NR
Dual therapy (sitagliptin + metformin): 100 mg/1,000 mg daily 100 mg/2,000 mg dailySitagliptin: 100 mg daily

Metformin:
1,000 mg daily
2,000 mg daily
Range

2 Fair
0 Good
670–1,091
24–54
53.2–54.2 (9.1–10.2)
44.7–59
46.0–58.2
21.4–30.2
Dual therapy: 100 mg/2,000 mg dailySitagliptin: 100 mg daily

Metformin: 1,000 mg–3,000 mg daily

Abbreviations: NR, not reported; SD, standard deviation.

a

Unless otherwise noted, data presented are the range across treatment groups for mean and standard deviation.

b

Williams-Herman et al, 2009 is a 30-week extension of Goldstein et al, 2007.

c

Williams-Herman 2010 is an additional 50 week extension of Goldstein 2007 and Williams-Herman 2009.

From: Results

Cover of Drug Class Review: Newer Diabetes Medications, TZDs, and Combinations
Drug Class Review: Newer Diabetes Medications, TZDs, and Combinations: Final Original Report [Internet].
Jonas D, Van Scoyoc E, Gerrald K, et al.
Portland (OR): Oregon Health & Science University; 2011 Feb.
Copyright © 2011, Oregon Health & Science University.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.